IN A NUTSHELL 🚀 Trump unveils a comprehensive AI Action Plan, aiming to slash bureaucratic red tape and boost American innovation. 🌐 The plan emphasizes enhancing export capabilities and constructing billion-dollar infrastructure projects to secure U.S. dominance. 🔧 Fast-tracking permits for data centers and launching workforce programs are key strategies to advance the AI agenda. 📈 The administration’s efforts focus …
Read More »Tag Archives: Fierce
NASA’s Sahara Shock: The Desert’s Mysterious Greening Sparks Fierce Battle Between Climate Optimists, Deniers, and Geopolitical Hawks – Rude Baguette
NASA’s Sahara Shock: The Desert’s Mysterious Greening Sparks Fierce Battle Between Climate Optimists, Deniers, and Geopolitical Hawks Rude Baguette Source link
Read More »Replimune's shares crater as FDA rejects melanoma drug – Fierce Biotech
Replimune’s shares crater as FDA rejects melanoma drug Fierce Biotech Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance statnews.com Replimune drug rejected by FDA; Omega raises $647M biotech fund Yahoo Finance Replimmune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment BioSpace Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment Barron’s Source link
Read More »Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy – Fierce Biotech
Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Fierce Biotech We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress statnews.com Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug Yahoo Finance Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths The New York Times …
Read More »Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion – Fierce Pharma
Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion Fierce Pharma BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial BioSpace Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes Endpoints News Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here’s What Investors Are Thinking Stocktwits Luspatercept Plus …
Read More »